```html

Jaundice due to Hepatitis B

Overview

Jaundice is a yellowish discoloration of the skin, sclerae (the whites of the eyes), and bodily fluids caused by elevated levels of bilirubin in the blood. When jaundice occurs as a manifestation of hepatitis B infection, it signals that the liver is inflamed and its ability to process bilirubin is impaired.

Who it affects: Hepatitis B virus (HBV) infection can occur at any age, but the highest prevalence is found in regions where perinatal (mother‑to‑baby) transmission is common, such as sub‑Saharan Africa and East Asia. In the United States, an estimated 850,000 to 2 million people are chronically infected with HBV, and about 2–5 % of these individuals develop acute liver inflammation with jaundice each year.<sup>[1][2]</sup>

Prevalence of jaundice in HBV: Among patients with acute HBV, 30–50 % experience jaundice, while in chronic infection jaundice is less common and usually indicates a flare‑up or progression to cirrhosis.<sup>[3]</sup>

Symptoms

Jaundice is often accompanied by a cluster of other signs that reflect liver dysfunction. The following list includes both the classic yellow discoloration and associated systemic symptoms.

Primary symptom

• Yellowing of skin and eyes: Most noticeable on the face, palms, and the white part of the eyes. It usually begins on the face and spreads downward.

Additional symptoms of hepatitis B–related jaundice

• Dark urine: Bilirubin excreted by the kidneys turns urine brown‑orange.
• Pale or clay‑colored stools: Reduced bile flow decreases stool pigment.
• Fatigue and weakness: The liver’s reduced metabolic capacity leads to low energy.
• Abdominal discomfort: Especially in the right upper quadrant where the liver sits.
• Loss of appetite, nausea, and vomiting: Common during the acute phase.
• Fever and chills: May accompany acute infection.
• Joint and muscle aches: Often present in the prodromal phase before jaundice appears.
• Itchy skin (pruritus): Accumulated bile salts can cause itching.
• Weight loss: Secondary to decreased appetite and prolonged illness.

Causes and Risk Factors

Jaundice occurs when HBV damages hepatocytes, impairing bilirubin conjugation and excretion. The underlying cause is the viral infection itself, but several factors increase the likelihood of developing jaundice.

Direct causes

• Acute HBV infection: The initial immune response attacks infected liver cells, leading to inflammation and bilirubin buildup.
• HBV flare in chronic infection: Reactivation of the virus (often due to immunosuppression or co‑infection) can cause sudden liver inflammation and jaundice.
• Co‑existing liver disease: Alcoholic liver disease, non‑alcoholic fatty liver disease (NAFLD), or hepatitis C can compound liver injury.

Risk factors for infection and for developing jaundice

• **Perinatal transmission** – infants born to HBV‑positive mothers.
• **Sexual contact** with an infected partner (unprotected sex, especially with multiple partners).
• **Percutaneous exposure** – sharing needles, tattooing, or medical procedures with non‑sterile equipment.
• **Household or occupational exposure** – caring for an HBV‑positive individual without proper precautions.
• **Immunosuppression** – chemotherapy, high‑dose steroids, HIV infection, or biologic agents increase the chance of a flare.
• **Older age and male sex** – associated with a higher risk of progression to severe liver disease.

Diagnosis

Accurate diagnosis requires confirming HBV infection and establishing that jaundice is a result of hepatic dysfunction.

Laboratory tests

• Serologic markers:
  • HBsAg (hepatitis B surface antigen) – indicates current infection.
  • HBc IgM (core IgM antibody) – marks acute infection.
  • HBeAg and anti‑HBe – provide information about viral replication and infectivity.
• Liver function panel: Elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) often exceed 10‑fold the upper limit of normal in acute hepatitis. Bilirubin (total and direct) levels are usually >2.5 mg/dL in clinically evident jaundice.
• Coagulation profile: Prothrombin time (PT/INR) may be prolonged, indicating impaired synthetic function.
• Complete blood count (CBC): May show mild leukopenia or thrombocytopenia in advanced disease.

Imaging studies

• Abdominal ultrasound: First‑line to assess liver size, echotexture, and rule out biliary obstruction.
• Transient elastography (FibroScan): Non‑invasive measurement of liver stiffness, useful for chronic HBV monitoring.
• CT or MRI: Reserved for complicated cases (e.g., suspicion of hepatocellular carcinoma or portal vein thrombosis).

Other assessments

• Liver biopsy: Rarely needed for jaundice; may be performed if there is diagnostic uncertainty or to stage fibrosis in chronic disease.
• Viral load (HBV DNA PCR): Quantifies replication; guides antiviral therapy.

Treatment Options

Treatment aims to reduce viral replication, support liver function, and manage symptoms of jaundice.

Antiviral medications

• Tenofovir disoproxil fumarate (TDF) or Tenofovir alafenamide (TAF): First‑line agents with a high barrier to resistance.
• Entecavir: Equally effective; preferred if tenofovir is contraindicated.
• Therapy is generally recommended for patients with:
  • ALT >2× ULN plus HBV DNA ≥20,000 IU/mL, or
  • Evidence of liver fibrosis/cirrhosis, or
  • HBV flares with jaundice.

Supportive care for jaundice

• Hydration and electrolytes – oral or IV fluids if vomiting or poor intake.
• Nutrition – high‑protein, low‑fat diet; avoid alcohol and hepatotoxic substances.
• Pruritus relief – antihistamines (e.g., diphenhydramine) or bile‑acid sequestrants (e.g., cholestyramine).
• Phototherapy is rarely needed in adults but may be considered in severe cholestasis.

Procedures

• Liver transplant: Reserved for acute liver failure or decompensated cirrhosis unresponsive to medical therapy.
• Therapeutic plasmapheresis: Occasionally used in fulminant hepatitis to remove circulating bilirubin and inflammatory mediators.

Lifestyle modifications

• Complete abstinence from alcohol.
• Maintain a healthy weight (BMI < 25) to limit NAFLD progression.
• Vaccinate against hepatitis A and C to prevent co‑infection.

Living with Jaundice due to Hepatitis B

While jaundice itself is often transient, the underlying hepatitis B may be chronic. The following tips help patients manage daily life while protecting liver health.

• Medication adherence: Take antivirals exactly as prescribed. Use pill organizers or reminder apps.
• Monitor symptoms: Keep a log of fatigue, itching, stool color, and any new abdominal pain. Report changes promptly.
• Regular follow‑up: Labs (ALT, HBV DNA, bilirubin) every 3–6 months for chronic infection; more frequently during a flare.
• Dietary advice:
  • Eat small, frequent meals rich in fruits, vegetables, whole grains, and lean protein.
  • Limit saturated fat, sugar, and processed foods that stress the liver.
  • Stay well‑hydrated; aim for ≥2 L of water daily unless fluid-restricted.
• Exercise: Moderate aerobic activity (150 min/week) improves insulin sensitivity and reduces fatty liver risk.
• Protective measures: Use condoms, avoid sharing needles, and follow universal precautions if you work in health care.
• Psychosocial support: Join hepatitis B support groups or seek counseling; chronic liver disease can affect mental health.

Prevention

Because jaundice is a downstream effect of HBV infection, preventing HBV acquisition or reactivation is paramount.

• Vaccination: The hepatitis B vaccine is >95 % effective. The CDC recommends a 3‑dose series for all infants, unvaccinated adults at risk, and health‑care workers.
• Maternal prophylaxis: Infants born to HBsAg‑positive mothers should receive hepatitis B immune globulin (HBIG) and the first vaccine dose within 12 hours of birth.
• Safe sex practices: Consistent condom use reduces transmission by ~70 %.
• Injection safety: Use only sterile needles; never share syringes.
• Screening: Test pregnant women, blood donors, and high‑risk groups for HBsAg.
• Avoid alcohol and hepatotoxic drugs: Reduces cumulative liver injury, lowering the chance of jaundice during a flare.

Complications

If jaundice and the underlying hepatitis B are not adequately treated, several serious complications can develop.

• Acute liver failure: Rapid loss of hepatic function, coagulopathy, and encephalopathy; high mortality without transplant.
• Chronic hepatitis and cirrhosis: Progressive fibrosis leading to portal hypertension, ascites, variceal bleeding.
• Hepatocellular carcinoma (HCC): HBV is a leading cause of liver cancer worldwide; risk increases with cirrhosis and age.
• Renal dysfunction (HBV‑associated glomerulonephritis): Immune complex deposition can lead to proteinuria and nephrotic syndrome.
• Extra‑hepatic manifestations: Polyarteritis nodosa, mixed cryoglobulinemia, and peripheral neuropathy.

When to Seek Emergency Care

References

1. World Health Organization. Global Hepatitis Report 2022. WHO; 2022.
2. Centers for Disease Control and Prevention. Hepatitis B FAQs for Health Professionals. CDC; 2023.
3. Mayo Clinic. “Hepatitis B: Symptoms and causes.” Updated 2024.
4. Cleveland Clinic. “Jaundice: When to see a doctor.” Accessed May 2026.
5. American Association for the Study of Liver Diseases (AASLD). “Guidelines for treatment of chronic hepatitis B.” 2023.
6. National Institutes of Health. “HBV DNA testing and its role in management.” NIH; 2022.

```